Purpose Tumor endothelial marker 8 (TEM8) has been reported to be upregulated in both tumor cells and tumorassociated endothelial cells in several cancer types. TEM8 antagonists and TEM8-targeted delivery of toxins have been developed as effective cancer therapeutics. The ability to image TEM8 expression would be of use in evaluating TEM8-targeted cancer therapy.
Introduction
Antiangiogenesis is a promising strategy for the treatment of cancer and targeting the endothelial cells that line tumorinfiltrating blood vessels has gained widespread attention and support [1] [2] [3] . The upregulation of tumor endothelial marker 8 (TEM8) on the endothelial cells of blood vessels has been observed in several tumor types in both humans and mice, making this receptor a particularly promising new candidate for future tumor angiogenesis targeting studies [4, 5] .
TEM8, also known as anthrax toxin receptor 1 (ANTXR1), is one of the two cell surface anthrax toxin receptors. It shares the extracellular von Willebrand factor type A (vWA) domain with the other receptor for anthrax toxin called capillary morphogenesis protein 2 (CMG2/ ANTXR2) [6, 7] . TEM8 is reported to be selectively overexpressed on both tumor endothelial and cancer cells during tumor angiogenesis, whereas CMG2 is more widely expressed in normal tissues [8] . TEM8 links extracellular matrix components with the actin cytoskeleton to promote cell adhesion and cell spreading [9] . Moreover, TEM8 appears to regulate endothelial cell migration and tubule formation [10] .
It has been reported that TEM8 may be a useful marker to identify tumor-associated microvessels and that elevated levels of TEM8 are associated with disease progression of breast cancer [11] . Cullen et al. [12] found that host-derived TEM8 promotes the growth of certain tumors and suggested that TEM8 antagonists may have utility in the development of new anticancer therapies. Fernando and Fletcher [13] successfully developed a fusion protein that targets TEM8 and disrupts tumor vasculature by promoting localized thrombosis.
Anthrax toxin, which contains protective antigen (PA), lethal factor, and edema factor, enters target cells through a multistep mechanism. The full-length PA (PA83, 83 kDa) binds cell surface receptors and is cleaved to PA protein (PA63, 63 kDa) by cellular furin-like enzymes [8, 14, 15] . The crystal structure of PA protein contains four domains that, according to mutational and biochemical analyses [16, 17] , are associated with different functions. Among these, domain IV (residues 596-735) is believed to be a critical receptor-binding region for the binding of the cellular receptor (either TEM8 or CMG2) of PA [15, 16, 18] . A MIDAS motif present in the integrin-like inserted (I) domain of ANTXR1/TEM8 mediates the binding of the D683 residue of PA domain IV.
Several studies have been conducted based on the interaction between PA and TEM8 or CMG2. Chen et al. [8] used phage display to select PA mutants that preferentially bind to TEM8 over CMG2 in order to target tumors using modified anthrax toxin PA. Duan et al. [19] engineered an antibody-like protein, TEM8-Fc, that consists of the PAbinding domain of human TEM8 linked to the Fc portion of human immunoglobulin G 1 . They then showed that TEM8-Fc can protect J774A.1 macrophage-like cells against anthrax toxin challenge in a dose-dependent manner, and it could suppress the growth and metastasis of xenografted human tumors in athymic nude mice.
In this study, we designed a peptide 13-mer based on the small loop (amino acids 680-692) [16] in domain IVof PA (Fig. 1) 18 F labeling on this amino-acid residue. The final 13-mer peptide is KYNDRLPLYISNP (denoted as "QQM"). In vitro cell binding and ELISAs (described below) demonstrated that this peptide binds specifically to the extracellular domain of TEM8, and we labeled it with 18 F for positron emission tomography (PET) imaging of TEM8 expression patterns in tumor xenograft models.
Materials and methods

General
The linear 13-meric peptide QQM was prepared via standard solid-phase Fmoc chemistry with an automated peptide synthesizer (CS Bio, Menlo Park, CA). No-carrieradded 18 F-F − was produced from an in-house GE Healthcare PETtrace cyclotron. Reversed-phase extraction C 18 Sep-Pak cartridges (Waters) were pretreated with ethanol (5 ml) and water (10 ml) before use. The syringe filter and polyethersulfone membranes (pore size 0.22 mm, diameter 13 mm) were purchased from Nalge Nunc International. Analytical and semipreparative reversed-phase highperformance liquid chromatography (RP-HPLC) were performed on a Waters 600 chromatography system with a Waters 996 photodiode array detector and Beckman 170 radioisotope detector. A C 18 Vydac protein and peptide column (218TP510; 5 μm, 250×10 mm) was used for peptide purification. The flow was set at 5 ml/min using a The small loop (purple) of domain IV (yellow) is packed in the interface between PA domains II (green) and TEM8/CMG2 (orange). The 13-mer QQM peptide was designed from the sequence of the small loop gradient system starting from 95% solvent A (0.1% trifluoroacetic acid in water) and 5% solvent B (0.1% trifluoroacetic acid in acetonitrile) (0-2 min) and ramped to 35% solvent A and 65% solvent B at 32 min. The flow rate of the analytical HPLC was set at 1 ml/min using the same gradient system, but with a different C 18 Vydac column (218TP54; 5 μm, 250×4.6 mm). The UV absorbance was monitored at 218 nm and the identification of the peptides was confirmed based on the UV spectrum acquired (using a photodiode array detector) and mass spectrometry. [20, 21] . The QQM labeling procedure (Fig. 2 ) was as follows: QQM (300 μg) dissolved in 150 μl anhydrous dimethyl sulfoxide (DMSO) was added to dried 18 F-NFP in a 1 ml reaction vial, followed by adding 20 μl of diisopropylethylamine. The reaction mixture was allowed to stand at room temperature for 10 min and then quenched with 800 μl of 5% aqueous acetic acid solution. The labeled peptide was purified by RP-HPLC on a semipreparative C 18 column. The desired fractions containing 18 F-FP-QQM were collected and diluted with 20 ml of water. The identity of 18 F-FP-QQM was confirmed by HPLC by coinjection with the cold standard FP-QQM. After trapping with a preactivated C 18 Sep-Pak cartridge, the product was washed 
Synthesis of FP-QQM
Cell culture and animal models
The MDA-MB-435 human melanoma cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA). The UM-SCC1 cell line was obtained from the University of Michigan. Both cell lines were grown in high glucose Dulbecco's modified Eagle's medium (Invitrogen) supplemented with fetal bovine serum (10%, volume percentage) and 1% antibiotics (penicillin 100 U/ml, plus streptomycin 100 μg/ml) at 37°C in a humidified incubator containing 5% CO 2 .
The MDA-MB-435 tumor model was generated by subcutaneous injection of 5×10 6 cells into the right front flank of female athymic nude mice (Harlan Laboratories). The UM-SCC1 tumor model was established by injection of 6×10 6 cells into the right front flank of the mice with a 100 μl total volume consisting of a 1:1 ratio of sterile PBS and Matrigel (Becton Dickinson). The mice were used for PET studies when the tumor volume reached about 200-500 mm 3 (about 2-3 weeks for MDA-MB-435 and about 5-6 weeks for UM-SCC1). All animal studies were conducted in accordance with the principles and procedures outlined in the NRC Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee (IACUC) of the Clinical Center, National Institutes of Health.
Expression and purification of recombinant TEM8 vWA domain
The pGEX4T-1 plasmid encoding the human TEM8 vWA domain was a generous gift from Dr. Jianping Xiong (Massachusetts General Hospital, Charlestown, MA). The protein expression and purification were performed following previously reported procedures [6] . Briefly, the pGEX4T-1 plasmid was transformed to TOP10 chemically competent E. coli (Invitrogen), and selected single colonies were shaken in 1 l lysogeny broth medium containing 100 μg/ml ampicillin at 37°C and 250 rpm. After induction with 0.1 mM isopropyl-D-thiogalactopyranoside for 4 h, the E. coli cells were harvested for protein purification. All subsequent purification steps were performed on ice or at 4°C. After being resuspended in buffer containing 100 mM Tris, 300 mM NaCl and 5 mM EDTA (pH 8.2), cells were disrupted by sonication, and cell debris was removed by centrifugation at 14,000 rpm for 30 min. The supernatant was incubated with 2 ml pre-equilibrated glutathione Sepharose 4B beads (GE Healthcare, Piscataway, NJ) for 2 h. Then the beads were washed with elution buffer (2, 15, 40, and 100 mM reduced glutathione in 50 mM Tris-HCl, pH 8.0). The protein eluates were collected separately and pooled after SDS-PAGE analysis.
In vitro cell binding assay TEM8 binding assay was performed to determine binding affinities of QQM peptide. Briefly, UM-SCC1 cells (Sibtech, Brookfield, CT) were trypsinized and resuspended in PBS containing 50 mM HEPES, 1 mM CaCl 2 , 5 mM MgCl 2 , 0.5% w/v bovine serum albumin (BSA) and 0.3 mM NaN 3 . Incubation was conducted in 96-well plates with each well containing 1 x 10 5 cells, 500 nCi (18.5 KBq) of 18 F-FP-QQM, and 0-2,000 nM of unlabeled QQM in a total volume of 200 μl for 45 min on a shaker at room temperature. After incubation and washing with PBS, hydrophilic polyvinylidene fluoride filters were collected and the radioactivity was determined using a gamma counter (1480 Wizard 3, Perkin-Elmer). Binding results were expressed as the percent of total counts, and IC 50 values were calculated using Prism software (GraphPad, La Jolla, CA). ELISA A modified ELISA was used to examine the binding affinity of QQM peptide to the extracellular domain of TEM8. In brief, a PVC microtiter plate (Millipore, Billerica, MA) was coated with 100 μl per well of the captured QQM peptide, at a concentration of 100 μg/ml in carbonate/bicarbonate buffer (pH 9.6), with overnight incubation at 4°C in a humidified chamber. The coated wells were then blocked for 2 h with 5% BSA/PBS and incubated with the vWA domain of TEM8 protein at different concentrations, from 5 nM to 3 μM, at 37°C for 90 min. After washing with PBST (0.1% Tween-20 in PBS) four times, the wells were incubated with goat antihuman TEM8 antibody (1:500, R&D Biosciences) and then with horseradish peroxidase-conjugated donkey antigoat secondary antibody (1:10,000; Jackson ImmunoResearch Laboratories, West Grove, PA). The signal was measured colorimetrically using a 96-well plate reader (BioTek Synergy 2, Winooski, VT) at a wavelength of 450 nm after adding tetra-methylbenzidine and hydrogen peroxide.
Tumor tissue TEM8 expression by western blotting For western blotting, the total protein from each of the UM-SCC1 and MDA-MB-435 tumor samples was extracted in NP40 cell lysis buffer (Invitrogen). The concentration of total protein was determined using a microBCA protein assay kit (Pierce Biotechnology, Rockford, IL). After SDS-PAGE separation of 10 μg of total protein, the protein was transferred to a polyvinylidene fluoride membrane (Invitrogen, Carlsbad, CA) and incubated at room temperature with 5% non-fat milk blocking buffer. The blots were then incubated with either a goat anti-human TEM8 antibody (1:200, R&D) or a rabbit polyclonal antibody against β-actin (1:1,000, ab8227; Abcam) primary antibody for 1 h and subsequently labeled using appropriate horseradish peroxidase-conjugated donkey anti-goat or donkey antirabbit secondary antibodies (1:6,000; Jackson ImmunoResearch Laboratories, West Grove, PA), respectively, for 1 h. The bands were detected using an ECL western blotting detection system (GE Healthcare, Piscataway, NJ).
Fluorescent immunohistochemical staining
In order to determine the different expression patterns of TEM8 in tumors, frozen UM-SCC1 and MDA-MB-435 tumor tissue sections (5-8 μm) were fixed with cold acetone for 20 min and dried in the air. All the sections were blocked with 1% BSA for 30 min, and then incubated with goat antihuman TEM8 antibody (1:200, R&D) and rat anti-mouse CD31 antibody (1:500) for 1 h at room temperature. They were then visualized with Daylight 488-conjugated bovine anti-goat secondary antibody (1:500) or Cy3-conjugated donkey anti-rat secondary antibody (1:1,000; Jackson ImmunoResearch Laboratories), respectively. After five washing steps, the tissue slices were mounted with mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) and all slices were viewed by epifluorescence microscopy (Olympus X81).
Cell uptake of 18 F-FP-QQM
The UM-SCC1 and MDA-MB-435 cells were seeded into 24-well plates at a density of 1×10 5 cells per well and incubated overnight. The cells were incubated with about 37 kBq (1 μCi) per well of 18 F-FP-QQM at 37°C for 15, 30, or 60 min. In an experiment to block specific binding of 18 F-FP-QQM, the QQM peptide was added to UM-SCC1 cells in 24-well plates at a final concentration of 1 μM. The cells were then incubated at 37°C for 15, 30, and 60 min. To determine the internalized activity, additional samples of UM-SCC1 cells were washed with acid (50 mM glycineHCl/100 mM NaCl, pH 2.8) at different time points (15, 30 , and 60 min) after incubation with 18 F-FP-QQM at 37°C to remove the radioactivity bound to the cell surface. These tumor cells were then washed three times with chilled PBS and lysed by 0.1 N NaOH. The cell lysate was collected and measured using a γ counter (Packard, Meriden, CT). The cell uptake was expressed as a percentage of the decaycorrected total input radioactivity. All the experiments were performed twice with triplicate wells.
Small-animal PET imaging
PET scans and image analysis were performed using an Inveon microPET scanner (Siemens). Each UM-SCC1 or MDA-MB-435 tumor-bearing mouse was injected intravenously with 3.7 MBq (100 μCi) of 18 F-FP-QQM under isoflurane anesthesia (n=6/group). Static scans of duration 5 min were acquired at 15, 30, and 60 min after injection (p.i.), and 10-min scans were acquired at 2 h p.i. For the TEM8 receptor-blocking experiment, QQM (500 μg in 100 μl PBS per mouse) was coinjected with 3.7 MBq of 18 F-FP-QQM peptide into UM-SCC1 tumor mice, and 5-min static microPET scans were acquired at 1 h p.i. Images were reconstructed using the 2-dimensional ordered subsets expectation maximum algorithm without attenuation or scatter correction. Regions of interest (ROIs) over the tumor, normal tissue, and major organs were drawn on decay-corrected whole-body coronal images for each PET scan using the vendor software (ASI Pro 5.2.4.0). The radioactivity concentration (accumulation) within a tumor or an organ was obtained from mean pixel values within the multiple ROI volume, after conversion of the values to megabecquerels per milliliter per minute using a conversion factor assuming a tissue density of 1 g/ml. Imaging ROIderived percentage injected dose per gram of tissue (%ID/g) was calculated by dividing the ROI radioactivity concentration by the administered activity [22] .
Ex vivo biodistribution
Immediately after imaging at 1 or 2 h p.i. the tumor-bearing mice were killed. Blood, tumor, major organs, and tissues were collected and weighed wet. The radioactivity in the wet whole tissue was measured using a γ counter (Packard). The results are presented as %ID/g. For each mouse, the radioactivity of the tissue samples was calibrated against a known aliquot of the injected tracer and normalized to the mean body mass of each group. The results are expressed as means±SD (n=4 per group).
Statistical analysis
Quantitative data are expressed as means±SD. Means were compared using Student's t-test. P values of <0.05 were considered statistically significant. 
Results
QQM specifically binds to TEM8
We performed competitive cell binding assays and ELISAs to confirm the specific binding of QQM peptide to TEM8 protein. Since there was no commercially available TEM8-specific radioligand, we used 18 F-FP-QQM for homologous displacement. The IC 50 of QQM peptide binding to 293-TEM8 cells was 33.04 nM (Fig. 3a) In order to further confirm the binding affinity and specificity, we also expressed and purified the extracellular domain of TEM8 and performed an ELISA with the purified protein. As shown in Fig. 3b , the QQM peptide showed gradual binding saturation with increasing concentrations of the purified TEM8 protein, which suggests a specific binding of QQM to TEM8. The K d value was around 304 nM.
Vasculature-related TEM8 expression
The expression of TEM8 in UM-SCC1 and MB-MDA-435 tumors was assessed at the protein level by both western blotting and fluorescent immunohistochemical staining (Fig. 4) . Western blotting showed a distinct 60-kDa molecular weight band representing TEM8. As seen in Fig. 4a , the homogenized UM-SCC1 tumor tissue extract had much higher TEM8 expression than the MDA-MB-435 tumor tissue extract. The TEM8 distribution in the tumor was also evaluated by ex vivo fluorescent immunohistochemical staining. Representative images of CD31 and TEM8 receptor staining of UM-SCC1 and MDA-MB-435 tumor sections are shown in Fig. 4b . The intensity of TEM8 expression in UM-SCC1 tumor was substantially higher than that in MDA-MB-435 tumor, using the same scale. The green fluorescence of the TEM8 receptor was concentrated around the vessel-rich region and was partially overlaid with the red fluorescence of CD31, a vasculature marker. Much lower staining signals were observed in the MDA-MB-435 tumor sections.
Cell uptake and internalization of 18 F-FP-QQM Additionally, we developed QQM peptide as a PET imaging tracer by labeling it with a positron emitting radioisotope, 18 F (t 1/2 109.8 min). 18 F-FP-QQM was characterized in vitro by cell uptake assays in UM-SCC1 and MDA-MB-435 cells.
18 F-FP-QQM had significantly higher cell uptake efficiency in UM-SCC1 cells than in MDA-MB-435 cells (Fig. 5) . The UM-SCC1 cell uptake percentages of total input radioactivity were 6.21±0.21%, 8.35±0.17% and 8.34±0.64% at 15, 30, and 60 min, respectively. By contrast, the MDA-MD-435 cells showed only minimal uptake percentages of 0.49±0.23%, 0.65± 0.20%, and 0.50±0.13% at 15, 30, and 60 min, respectively. The uptake of 18 F-FP-QQM in UM-SCC1 was also effectively blocked in the presence of non-radiolabeled QQM peptide (0.48± 0.06%, 0.63 ± 0.07%, and 1.08 ± 0.13% at 15, 30, and 60 min, respectively). We used the acid wash experiment to remove 18 F-FP-QQM bound to the cell surface and determine the effectiveness of the internalization process. It was clear that 18 F-FP-QQM was almost completely internalized into UM-SCC1 cells after 15 min incubation at 37°C.
MicroPET imaging
Representative coronal microPET images of UM-SCC1 and MDA-MB-435 tumor-bearing mice (n=6/group) at 15, 30, 60 and 120 min after intravenous injection of 3.7 MBq (100 μCi) of 18 F-FP-QQM are shown in Fig. 6a . A plot of the ROI analysis results in UM-SCC1 and MDA-MB-435 tumors is shown in Fig. 6b . The UM-SCC1 tumors were clearly contoured with high contrast in relation to the MDA-MB-435 tumors at all time points after injection (3.73 ± 0.56 vs. 1.64 ±0.24 %ID/g at 30 min, 2.96 ±0.84 vs. 1.38 ±0.56 %ID/g at 60 min, and 2.04±0.22 vs. 1.00±0.44%ID/g at 60 min; P <0.01 at 30 min, P<0.05 at 60 min and 120 min).
18 F-FP-QQM was excreted mainly through the renal/urinary route, as reflected by very minimal liver uptake (8.47±1.19 %ID/g at 15 min, 4.23±3.20 %ID/g at 30 min, 3.84±2.49 %ID/g at 60 min, and 1.63±0.51 %ID/g at 120 min), and an initially high radioactive signal in the kidneys followed by rapid (Fig. 6c) . No bone uptake was observed, suggesting no defluoridation during the course of imaging studies.
Ex vivo biodistribution study
After microPET imaging at 1 h and 2 h p.i., the animals were killed for biodistribution studies and the results are shown in Fig. 7 . Consistent with the non-invasive micro-PET imaging results, the tumor uptake percentages were 3.45±0.95 %ID/g and 2.03±0.29 %ID/g at 60 min and 120 min p.i., respectively. The kidneys, lung and pancreas also showed prominent radioactivity accumulation, with uptakes of 5.21±2.67, 3.19±1.44 and 5.24±2.66 %ID/g, respectively, at 60 min.
Discussion
The fact that TEM8 is differentially expressed on tumor endothelium but shows limited expression in normal tissues [4] makes this receptor an attractive target for cancer imaging and therapy. Protective antigen is an essential part of anthrax toxin, serving as a cellular binding moiety and a delivery vehicle for translocation of lethal factor and edema factor into the cytosol of cells. It has been confirmed that the small loop of amino acids 680-692 within domain IVof PA is required for PA binding to cells [23, 24] . By taking advantage of the specific interaction between this small loop of PA and TEM8, we synthesized and developed a 13-mer peptide (QQM) probe for TEM8 imaging (Fig. 2) . It has been reported that Y 681 , N 682 , D 683 and P 686 are most important amino acid residues for receptor binding [16] . Thus, conjugation of the 18 F-containing prosthetic group on the lysine residue at the N-terminal of the peptide will not affect the receptor binding ability of this peptide. Indeed, competitive binding assays with homologous displacement indicates the QQM peptide possesses a high binding affinity for TEM8. In an ELISA assay using purified extracellular domain of TEM8, we also confirmed the specific interaction between QQM and TEM8.
The binding specificity was further confirmed by the fact that the in vitro cell uptake of 18 F-FP-QQM could be effectively blocked by the presence of an extra amount of "cold" QQM peptide. QQM peptide was rapidly internalized into TME8-expressing UM-SCC1 cells (Fig. 5) . It has been reported that oligomerization of PA63 triggers receptor-mediated endocytosis [25] . However, it is domain II (residues 259-487), not the domain IV, of PA that is involved in oligomerization [18, 26] . Thus, the mechanism of QQM-induced internalization after binding with TEM8 receptor remains to be elucidated.
It has been found that most of the genes expressed differentially in tumor endothelium are also expressed during angiogenesis of corpus luteum formation and wound healing. However, TEM8 expression is not detectable in developing corpus luteum, suggesting that it can be used as a tumor endothelial marker to differentiate between tumor angiogenesis and normal angiogenesis [4] . However, TEM8 has also been detected in a variety of tumor cell lines and in a human fibroblast cell line (MRC5) at both the mRNA and protein levels [11, 27] . TEM8 has also been found in stimulated endothelial progenitor cells [28] . Fernando and Fletcher [13] found that TEM8 protein expression colocalizes with both endothelial cells and CD34-positive cells. With fluorescent immunohistostaining, we found that TEM8 expression in UM-SCC1 tumor was substantially higher than in MDA-MB-435 tumor. The green fluorescence of the TEM8 receptor was concentrated around the vesselrich region and was partly overlain with CD31, a vasculature marker.
When labeled with 18 F through a 18 F-NFP prosthetic group, the resulting 18 F-FP-QQM peptide tracer showed enhanced uptake in vivo in UM-SSC1 tumors expressing high levels of TEM8 and only background uptake levels in vivo in MB-MDA-435 tumors expressing low levels of TEM8. The receptor specificity of 18 F-FP-QQM was further confirmed by effective blocking studies, both in vitro and in vivo. The results demonstrated that 18 F-FP-QQM can be used as a specific tracer to monitor TEM8 expression by non-invasive PET imaging. The 18 F-FP-QQM was excreted mainly through the renal/urinary route, as indicated by initially high radioactive signal in the kidneys and rapid clearance. Besides the kidneys, the lung and pancreas also showed relatively high radioactivity accumulation. PA of anthrax toxin binds to both TEM8 and another anthrax receptor, CMG2, and the latter has been reported to have approximately 1,000-fold higher affinity for PA [29] . We cannot exclude the possibility that these organs show relatively high expression of CMG2 [8] and thus 18 F-FP-QQM accumulation. Future investigations will involve the design of probes with more selectivity for TEM8 over CMG2.
In vivo PET imaging showed that the uptake of 18 F-FP-QQM in UM-SCC1 tumors reached a peak between 15 and 30 min after tracer injection and then decreased with time. The rapid clearance of the peptide from the tumor area was probably due to both the metabolic instability of the linear peptide and washout of the peptide from the circulation and the body. Our future work will seek to stabilize the QQM peptide with different molecular scaffolds.
Conclusion
With a rationally designed 13-mer peptide (QQM) based on the critical structure involved in PA-TEM8 interaction, we successfully imaged TEM8 overexpressing xenografts in a mouse model. To the best of our knowledge, this is the first time that TEM8 expression has been visualized with PET using a peptidic probe. The results demonstrate the feasibility of TEM8-based imaging. 
